Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$50.22
▼ $0.84 (-1.6%)
Market data updated: 09/19 04:00 AM
News analyzed: 09/19/2026
Market Cap
$216.72B
Day Range
$49.50 - $50.30
52-Week Range
$39.29 - $61.70
Beta
—
Next Earnings
28.10.2026
Support
$47.85
Resistance
$55.79
GSK is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+24.6% (1Y)
⚠️ Insufficient data for a reliable StockIQ Score
Only 3 of 7 categories available — Fundamental, Growth, Valuation, Quality unavailable.
Strengths: 2/12 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
MACD
MACD histogram is positive — rising momentum
Technical
Biggest negative driver
Calmar Ratio (return vs. drawdown)
Calmar: 0.34 (3y annualized return 10.3% / max drawdown 29.9%)
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 3 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 3
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
51
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
No data available
Quality
No data available
Value
No data available
Momentum
39
Risk
42
Sentiment
86
Fundamental
No data available
Institutional
100
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of GSK plc has focused on its financial and strategic maneuvers, particularly its efforts to fund the **Nuvalent acquisition** through a six-part dollar bond sale. Additionally, headlines highlight pricing discrepancies for its **shingles vaccine**, with significant cost variations between pharmacy and doctor’s office purchases. The company is also prominently featured in reports on the **expanding vaccines market**, including its role in **cancer vaccine development**, alongside competitors like BioNTech and Inovio. Regulatory milestones, such as the global approval of **Hibsago (bepirovirsen)** for hepatitis B and FDA priority review for a rectal cancer treatment, have drawn attention to GSK’s pipeline advancements.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about GSK plc American Depositary Shares (Each representing two Ordinary Shares). News trend score: 86. Reason: 8 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
15
🎯 Conviction (vs. Emotion)
50
Psychology
32
Fundamentals
—
Technical
39
Valuation
—
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
-1%
Market Narrative
58
Fundamental Reality
50
Narrative Gap
+8
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
GSK’s psychology is dominated by anchoring, as traders appear fixated on the 0.1% support level, despite muted panic or FOMO. The herding score suggests passive alignment with peers rather than aggressive positioning. Low volatility (ATR 0.97x baseline) and neutral RSI (36) imply no extreme emotional response. The key question: will traders break the near-term anchor, or will the 0.1% support hold as a psychological pivot?
Updated: 09/08/2026, 04:04 PM
What could change this?
👥 What the crowd believes
"Tracks 960+ Organizations and 2,100+ Drugs Across the Full Cancer Vaccine Pipeline — One-Year Analytical Tool Delivers Near-Real-Time Pipeline Alerts on 319 Targets/Antigens/Armor and 1,200+ Funding Rounds as GlaxoSmithKline, BioNTech, and Inovio Lead a Field"
"Bepirovirsen... was approved by Japan, marking the drug’s first authorization anywhere in the world"
"GSK Commences Six-Part Dollar Bond Sale to Help Fund Nuvalent Acquisition"
📈 10D Investor Psychology
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Thorstein Veblen — 80/100
🔴 Weakest match
Jesse Livermore — 28/100
🗣️ Why do they disagree?
The methodologies for GSK show a stark divide between those leaning bullish and those remaining cautious or neutral. Samuel Armstrong Nelson and Edgar Lawrence Smith both score near the top (97 and 100, respectively), with Nelson highlighting a favorable cycle position and Smith’s lack of dividend/growth data leaving room for optimism. In contrast, Jesse Livermore’s extreme low score (10) and verdict—rooted in his contrarian trend-following rules—suggests the stock may be moving against his preferred direction. Meanwhile, the middle-ground approaches, like Howard Marks (67) and Morgan Housel (59), acknowledge potential but flag concerns about valuation or market expectations. The lack of definitive data for Graham, Fisher, or Lynch leaves their frameworks inconclusive, while Veblen’s moderate score (80) implies alignment between growth and value—though not enough to override the more skeptical or neutral assessments.
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 100
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 80
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 75
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 62
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 52
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 51
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Peter Lynch
One Up on Wall Street (1989)
🟡 50
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Walter Bagehot
Lombard Street (1873)
🟡 50
Not enough balance-sheet data for a real Bagehot read
Key question
Does this company have enough liquidity to survive real stress?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 50
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 49
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟡 48
Mid-cycle — no strong signal either way
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 47
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 46
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 28
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Based on the last 282 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (2 bullish · 5 bearish · 3 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Total dividend per share paid each year, over the last 5 years.
| Ex-Dividend Date | Amount per Share |
|---|---|
| 14.8.2026 | $0.452 |
| 15.5.2026 | $0.461 |
| 14.5.2026 | $0.461 |
| 20.2.2026 | $0.486 |
| 19.2.2026 | $0.486 |
| 14.11.2025 | $0.417 |
| 13.11.2025 | $0.417 |
| 15.8.2025 | $0.428 |
| 14.8.2025 | $0.428 |
| 16.5.2025 | $0.429 |
| 15.5.2025 | $0.429 |
| 21.2.2025 | $0.401 |
Sentiment based on basic keywords (not AI) — 8 positive, 10 neutral, 2 negative out of the last 20 articles.
Yahoo · 17.9.2026
Yahoo · 17.9.2026
Yahoo · 17.9.2026
Yahoo · 16.9.2026
SeekingAlpha · 15.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
Proactive · 15.9.2026
SeekingAlpha · 14.9.2026
Zacks · 14.9.2026
Yahoo · 14.9.2026
Zacks · 14.9.2026
Yahoo · 14.9.2026
Moby · 14.9.2026
Yahoo · 14.9.2026
Benzinga · 14.9.2026
Barrons.com · 14.9.2026
StockIQ doesn't currently have enough real data to compute a reliable score for GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK) — only 3 of 7 categories are available right now. Rather than show a misleading number, this page shows which data is missing instead.
StockIQ doesn't give buy/sell recommendations — and for GSK specifically, there currently isn't enough real data (only 3 of 7 categories available) to state even a factual score reliably. Check back once more data is available.
GSK's technical score is 39/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: MACD histogram is positive — rising momentum; Price is above the SAR point — uptrend.
Based on the real signals StockIQ computed: Calmar: 0.34 (3y annualized return 10.3% / max drawdown 29.9%); Price is below the 50-day average; Price is below the 200-day average.
Yes — GSK has a real recorded dividend payment history on StockIQ. See the Dividends section on this page for the actual per-share amounts and dates.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 3 purchases and 0 sales out of the last 4 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| GSK plc | Open Market Purchase | 11.12.2025 | 1,470,000 | +1,470,000 | $19.00 |
| GSK plc | Open Market Purchase | 27.9.2024 | 2,791,930 | +2,791,930 | $8.00 |
| GSK plc | Open Market Purchase | 7.12.2023 | 3,300,000 | +3,300,000 | $5.00 |
| GSK PLC | Other Transaction | 16.9.2022 | 9,644,807 | -9,644,807 | $9.75 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
13,546,612 shares short as of 2026-08-31 · vs. 14,516,962 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
48.1% of trading volume this week was short selling, vs. 51.3% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology